Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
153.60    0.80 (0.52%)
Bid:
154.20
Ask:
154.80
Spread: 0.60 (0.389%)
Market Cap: £879.08m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

COVID-19 update

19 Mar 2020 07:00

ELEMENTIS PLC - COVID-19 update

ELEMENTIS PLC - COVID-19 update

PR Newswire

London, March 18

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No.596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Elementis plc

COVID-19 update

Suspension of the 2019 final dividend and relaxation of banking covenants

Elementis plc (“Elementis” or the “Group”), a global specialty chemicals company, today provides an update on the impact of the COVID-19 pandemic on its business and a change to its banking covenants.

Business performance

Up to 18 March 2020, the Group has experienced a solid start to the year with limited impact on production and demand from COVID-19. Our sites around the world remain open and are operating at normal levels. Trading and performance has been in line with our expectations, benefitting from efficiency actions implemented in 2019, with overall progress in Personal Care, Coatings and Talc. Market conditions are unchanged in Chromium.

The impact of COVID-19 however presents significant demand and operating uncertainty. Our immediate priorities remain safeguarding the health and wellbeing of our employees, and supporting our customers.

The Group is also taking steps to mitigate any potential material adverse financial impact, with focus on optimisation of cash flow via cost savings, working capital reduction and tight management of capex.

Liquidity, banking covenants and dividend

The Group has very ample liquidity, with in total over $300m immediately available. Total net debt for the Group, excluding lease liabilities under IFRS 16, was $454m at 31 December 2019, representing a ratio of 2.7x EBITDA*.

Elementis is a highly cash generative business, with average operating cash conversion of over 90% over the last 3 years. However, given market and economic uncertainties, the Group has taken two steps to provide additional financial headroom and preserve cash.

First, Elementis has secured a relaxation of its banking covenants from 3.25x to 3.75x net debt/EBITDA*. This will apply for two testing periods (i.e. 30 June 2020 and 31 December 2020).

Second, the Board has decided that given the uncertainties at this time it is prudent to preserve cash. Therefore, the 2019 final dividend of 4.4487 pence per share will no longer be proposed at the AGM scheduled for 29 April 2020. The cash impact of this decision to suspend the dividend is $33m in H1 2020. Future dividend decisions will be made as and when conditions normalise.

Paul Waterman, CEO of Elementis said:

“While our business performance to-date is in line with our expectations, we are acutely aware of the increased level of market and macroeconomic uncertainty. Our focus remains on what we can control, namely active cost and cash management. The relaxation of our banking covenants and the decision to suspend the final dividend will create material additional financial headroom to counter the potential impacts of the global COVID-19 crisis.”

Enquiries

Elementis plcJames Curran, Investor Relations Tel: 020 7067 2994

Tulchan Martin Robinson Tel: 020 7353 4200David Allchurch

Note: *Pre IFRS 16

Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.